The High Court has issued a "standover" on a writ seeking prevention of the transfer of Tk230 crore worth of shares of Novartis Bangladesh Ltd to Radiant Pharmaceuticals. Today, an HC division bench ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Novartis' CEO Vas Narasimhan on Tuesday, January 21, said the company remains committed to India, but it will take at least another decade before the Indian pharmaceutical market matures enough to ...

Novartis CEO Vas Narasimhan says the pharma industry hopes to work constructively with the new Trump administration. Trump says US will take 'take over' Gaza: 'We'll own it' Lady Gaga and Bruno ...

Greece on Monday prosecuted a pair of protected witnesses for alleged perjury in a long-running bribery probe involving the Swiss pharmaceutical firm Novartis, a justice source said. The man and woman ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry - where the American market accounts for almost a third of exports - during Donald Trump’s presidency.

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto ...

Swiss pharma giant Novartis (NOVN: VX) has filed a lawsuit against the US Department of Health and Human Services (HHS) over a proposed cash rebate model. The model relates to the 340B program, which ...

The U.S. Court of Appeals for the Federal Circuit ordered MSN Pharma of India to delay the launch of its Entresto generic “until further notice” as the court weighs Novartis’ bid to extend ...